ImmuPharma PLC's (LON:IMM) chairman Tim McCarthy caught up with Proactive's Andrew Scott to talk through the recently announced licensing deal worth almost US$100mln for Lupuzor - its treatment for the autoimmune disease lupus. US speciality drugs group Avion Pharmaceuticals will fund the US$25mln costs of a phase III clinical trial next year.
0 Comments